Posted in

Biomea Fusion, Inc. reports incentive grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion, Inc.Biomea Fusion, Inc.

Biomea Fusion, Inc.

REDWOOD CITY, Calif., May 1, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase a total of 80,250 shares of the company’s common stock. stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject in each case to each employee’s continued employment with the Company on such vesting dates. All awards described above were made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).

The awards described above were each granted as inducements to employees who joined the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The plan was adopted by Biomea’s board of directors on November 17, 2023.

About Biomea Fusion

Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules for the treatment of patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond with the target protein and offers a number of potential advantages over conventional noncovalent drugs, including greater target selectivity, lower drug exposure, and the ability to produce a deeper, achieve more sustainable operation. answer.

We use our proprietary FUSION™ system to discover, design and develop a pipeline of next-generation covalent-binding therapeutics designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We strive to have an outsized impact on the treatment of diseases for the patients we serve. We strive for healing.

Visit us at and follow us LinkedIn, Tweet And Facebook.

CONTACT: Contact: Investor Relations Chunyi Zhao, PhD Associate Director of Investor Relations & Corporate Development [email protected]